Resources for healthcare professionals

Clinical and educational material on ▼DEMOZUMAB (vigilanafine) for the add-on maintenance treatment of moderate-to-severe allergic rhinitis in adults and adolescents 12 years and older whose disease is inadequately controlled despite treatment with intranasal corticosteroids.3

Material library

Each item below is a piece of promotional or educational material in a different format. Open it in the viewer, or download it to review in Siguru.

SPRING-1 at a glance: the video's title card
Video

SPRING-1 at a glance

A short narrated summary of the pivotal trial design, primary endpoint and safety profile, with on-screen references.

MP4 · 1 min 56 s
HCP email: the top of the message
Email

HCP email: SPRING-1 results now published

A promotional email to UK prescribers announcing the publication of the SPRING-1 primary results.

PDF
DEMOZUMAB product overview page
Web page

DEMOZUMAB product overview page

A short product page for UK healthcare professionals with the licensed indication, SPRING-1 headline results and dosing.

Web page
Clear the Air campaign page
Non-promotional

Clear the Air: an allergic rhinitis awareness campaign

An unbranded public campaign page on the symptoms, triggers and impact of allergic rhinitis, and when to get help, organised and funded by Siguru Limited.

Web page
Speaker programme deck: the title slide
Speaker programme deck

SPRING-1: efficacy and safety of IL-47 blockade

The speaker programme slide deck on the pivotal trial, with study design, endpoints, subgroups and safety tables.

PDF · 13 slides
DEMOZUMAB product overview slide set: the title slide
Slide set

DEMOZUMAB product overview

A short slide set covering the indication, mechanism, dosing and the SPRING-1 results table, for use in one-to-one meetings.

PowerPoint (.pptx) · 9 slides

Prescribing information

Please refer to the Summary of Product Characteristics before prescribing DEMOZUMAB.

View prescribing information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Siguru Limited via the Siguru Reporting Tool or on 0800 987 6543.

References

  1. Mitchell PD, et al. Efficacy and safety of vigilanafine in adults and adolescents with moderate-to-severe allergic rhinitis: Results from the SPRING-1 randomised controlled trial. J Allergy Clin Immunol. 2025;155(3):687-696.
  2. Zhang H, Rahman S. IL-47 blockade in allergic disease: Mechanisms and therapeutic implications. Nat Rev Immunol. 2024;24(9):623-638.
  3. DEMOZUMAB (vigilanafine) Summary of Product Characteristics. Siguru Limited. December 2025.

UK-DMB-2026-014 | Date of preparation: October 2026